Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

 

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
R

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet Therapy vs. Quadruplet Therapy

By Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Rachid Baz
By Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Rachid Baz
92 views
February 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Videos
38:56
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate on the Use of MRD to Guide Transplant D…

Feat. H. Fernandez, N. Bejanyan
31:09
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Fu…

Feat. M. Alsina
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Feat. J. Brayer
16:00
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet…

Feat. R. Baz
18:44
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: How Much Is Enough in NDMM - Triplet …

Feat. K. Shain
20:54
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Updates on COVID-19 in Cancer Patients: Outcomes and Prevention

Feat. A. Giuliano
19:36
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Managing Hematologic Toxicities From Immunotherapeutic Agents

Feat. M. Jaglal
23:05
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Evaluation of Clonal Hematopoiesis in Patients With Solid Tumors: Ca…

Feat. E. Padron
22:37
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 Moffitt Cancer Center Updates on the Role of CAR T-Cells in Lym…

Feat. F. Locke
26:22
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 State of the Art: Best Frontline Therapy for CLL

Feat. J. Pinilla-Ibarz
25:53
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center's Updates on Treatment of R/R DLBCL: Inte…

Feat. S. Gaballa
34:29
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Moffitt Cancer Center Debate: Should NGS Be Reported in All Newly Di…

Feat. B. Shah, H. Saeed
27:27
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

2022 State of the Art Frontline Management of the HR-MDS

Feat. R. Komrokji
22:48
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Using Molecular Monitoring to Guide Therapy in AML: Interactive Case…

Feat. K. Sweet